I think the Brilacidin-OM could finish before the AVXL trial too. It should be pretty clear-cut -- either Bril-OM works well enough, for a large enough percentage of patients to make it approvable, or it doesn't.

If the FDA insists on a study of long-term effects, they could drag the AVXL trail on. That would be a tragedy -- even if their drug only works for a relatively short time, it will make a huge difference for patients and their families.